Search
for
Sort by
Research 181–210 of 1000+
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
- Recursos manuais aplicados para terapia capilar: tratamentos da alopecia androgenética masculina
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Recent Advances in Drug Development for Hair Loss
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle
- Dermatological Indications: Alopecia Areata
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Effects of oxytocin receptor agonists on hair growth promotion
- Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
- Autoinmune Alopecia/Alopecia Areata
- Treatments for alopecia areata: a network meta-analysis
- Targeted immunotherapy for hair regrowth and regeneration
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- An Updated in the Management of Alopecia Areata
- Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs
- Skin Biology and Ageing
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Towards cell-based therapy of alopecia areata: Autologous human Vδ2+ Foxp3+ γδTreg cells restore hair-follicle immune privilege and promote hair regrowth in human alopecia areata models ex vivo and in vivo
- Successful treatment of alopecia areata‐associated trachyonychia with baricitinib
- An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population